AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33534047 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 64
Study 33534047 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 40mg bid for 3 days followed by 20mg bid for 3 days
Number of subjects: 64
Study 33534047 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 64
Study 32452590 — intervention group
Group type: EXPERIMENTAL
Intervention: 23°C environment
Number of subjects: 20
Study 32452590 — intervention group
Group type: COMPARATOR
Intervention: 26°C environment
Number of subjects: 20
Study 35279972 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐S
Number of subjects: 132
Study 35279972 — intervention group
Group type: COMPARATOR
Intervention: ETT
Number of subjects: 132
Study 34886746 — intervention group
Group type: EXPERIMENTAL
Intervention: Castor oil (60 mL)
Number of subjects: 70
Study 34886746 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (60 mL, placebo)
Number of subjects: 70
Study 34605221 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (60%-70% HRR)
Number of subjects: 19
Study 34605221 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise (30%-40% HRR)
Number of subjects: 19
Study 34605221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 19
Study 34605221 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 19
Study 32081302 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 0
Study 32081302 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 0
Study 34937245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration atropine (0.01%) eye drops
Number of subjects: 30
Study 32060260 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic study on snoring
Number of subjects: 408000
Study 32060260 — intervention group
Group type: COMPARATOR
Intervention: Polygenic scores (PGS) to predict recent snoring and probable obstructive sleep apnoea (OSA)
Number of subjects: 408000
Study 32060260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analyses
Number of subjects: 408000
Study 36412382 — intervention group
Group type: EXPERIMENTAL
Intervention: High tidal volume (HTV) ventilation, 12-15 mL/kg (group H)
Number of subjects: 56
Study 36412382 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume (LTV) ventilation, 6-8 mL/kg (group L)
Number of subjects: 56
Study 36412382 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of HTV and LTV
Number of subjects: 56
Study 32063059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 10 mg
Number of subjects: 490
Study 32063059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Number of subjects: 490
Study 32063059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 50 mg
Number of subjects: 490
Study 32063059 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg (positive control)
Number of subjects: 490
Study 32063059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study 35241124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spinal manipulation
Number of subjects: 80
Study 35241124 — intervention group
Group type: COMPARATOR
Intervention: Simulated lumbar spinal manipulation (placebo)
Number of subjects: 80
Study 35241124 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity measured using the Numeric Pain Rating Scale
Number of subjects: 80
Study 35241124 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's expectation measured using a Likert scale
Number of subjects: 80
Study 34018433 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD-PLD
Number of subjects: 48
Study 34018433 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-PLD
Number of subjects: 48
Study 34018433 — intervention group
Group type: COMPARATOR
Intervention: ASD-Video
Number of subjects: 48
Study 34018433 — intervention group
Group type: COMPARATOR
Intervention: TD-Video
Number of subjects: 48
Study 34984488 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-spherical polyvinyl alcohol (ns-PVA)
Number of subjects: 84
Study 34984488 — intervention group
Group type: COMPARATOR
Intervention: Calibrated hydrogel microspheres (Embozene)
Number of subjects: 84
Study 32639545 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based povidone-iodine
Number of subjects: 661
Study 32639545 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based povidone-iodine
Number of subjects: 661
Study 32639545 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based chlorhexidine
Number of subjects: 661
Study 33860839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids (intervention group)
Number of subjects: 0
Study 33860839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hearing aids)
Number of subjects: 0
Study 34491022 — intervention group
Group type: EXPERIMENTAL
Intervention: aboBoNT‐A 50 U (5 injections of 0.1 mL each)
Number of subjects: 301
Study 34491022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 33350959 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined conventional and digital education through WhatsApp Messenger
Number of subjects: 80
Study 33350959 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral health education
Number of subjects: 80
Study 36325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruptive Mood Dysregulation Disorder (DMDD)
Number of subjects: 130
Study 36325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention‐Deficit/Hyperactivity Disorder (ADHD)
Number of subjects: 130
Study 36325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Disorder (ANX)
Number of subjects: 130
Study 36325887 — intervention group
Group type: COMPARATOR
Intervention: Healthy Volunteers
Number of subjects: 130
Study 36325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Sample
Number of subjects: 130
Study 34270797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg q2w (baseline weight < 60 kg)
Number of subjects: 618
Study 34270797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg q2w (baseline weight ≥ 60 kg)
Number of subjects: 618
Study 34270797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 100 mg q2w (baseline weight < 30 kg)
Number of subjects: 618
Study 34270797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg q2w (baseline weight 30-< 60 kg)
Number of subjects: 618
Study 34270797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg q4w (baseline weight ≥ 30 kg)
Number of subjects: 618
Study 34270797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 32267205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose regimen (TDF 200 mg, efavirenz 400 mg, lamivudine 300 mg)
Number of subjects: 184
Study 32267205 — intervention group
Group type: COMPARATOR
Intervention: Standard dose regimen
Number of subjects: 184
Study 32267205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose regimen
Number of subjects: 184
Study 32267205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose regimen and Standard dose regimen
Number of subjects: 184
Study 35562792 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week adapted mindfulness-based stress management program
Number of subjects: 42
Study 35562792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 32348700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined screening and treatment program targeting psychological distress
Number of subjects: 349
Study 35197490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) sessions daily over five consecutive days
Number of subjects: 34
Study 32525955 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation group (n = 11)
Number of subjects: 21
Study 32525955 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 21
Study 34269457 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute delivery of RBC concentrates (RCC) and whole blood (WB)
Number of subjects: 44
Study 34269457 — intervention group
Group type: COMPARATOR
Intervention: Control group (storage under conventional conditions at 4 ± 2°C)
Number of subjects: 44
Study 32532687 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccine
Number of subjects: 20
Study 32532687 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline injection
Number of subjects: 20
Study 36443929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral‐theory‐based psychoeducation (CBT)
Number of subjects: 40
Study 36443929 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulators (NMD)
Number of subjects: 40
Study 36443929 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI)
Number of subjects: 40
Study 34402327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian Improved Surname Geocoding (BISG) algorithm
Number of subjects: 0
Study 34402327 — intervention group
Group type: COMPARATOR
Intervention: NJ‐SHO reported race/ethnicity values
Number of subjects: 0
Study 34402327 — intervention group
Group type: EXPERIMENTAL
Intervention: BISG probabilities
Number of subjects: 0
Study 34402327 — intervention group
Group type: EXPERIMENTAL
Intervention: BISG algorithm
Number of subjects: 0
Study 32365303 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL+FRU+PEC+ALG (16% maltodextrin+fructose+pectin‐alginate)
Number of subjects: 14
Study 32365303 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL+FRU (16% maltodextrin+fructose)
Number of subjects: 14
Study 32365303 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 14
Study 32703048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal endoscope assisted suction cutter
Number of subjects: 82
Study 32703048 — intervention group
Group type: COMPARATOR
Intervention: Small-cut trimming
Number of subjects: 82
Study 32862421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco exposure
Number of subjects: 1826
Study 32862421 — intervention group
Group type: COMPARATOR
Intervention: Control (non-tobacco users)
Number of subjects: 1826
Study 36243742 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress induction
Number of subjects: 0
Study 36243742 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 34614061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate onlays (IPS e.max CAD)
Number of subjects: 11
Study 34614061 — intervention group
Group type: COMPARATOR
Intervention: Feldspathic ceramic onlays (Vita Mark II)
Number of subjects: 11
Study 36107715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2/3 receptor availability (BPND) in people who smoke
Number of subjects: 24
Study 36107715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition assessment using the CogState battery (International Shopping List) in people who smoke
Number of subjects: 24
Study 36107715 — intervention group
Group type: COMPARATOR
Intervention: Healthy-controls (N=25)
Number of subjects: 24
Study 32167794 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture (AA group n = 48)
Number of subjects: 96
Study 32167794 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (PA group n = 48)
Number of subjects: 96
Study 32167794 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture (AA group)
Number of subjects: 96
Study 32167794 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (PA group)
Number of subjects: 96
Study 34003351 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (NCRT)
Number of subjects: 256
Study 34003351 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mrT3 substage, extramural venous invasion (EMVI) grading, mucinous adenocarcinoma, mesorectal fascia involvement, elevated pretreatment carcinoembryonic antigen level
Number of subjects: 256
Study 34003351 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 substage, EMVI grading, NCRT
Number of subjects: 256
Study 34003351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms constructed from baseline MRI characteristics
Number of subjects: 256
Study 34278530 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (CBT)
Number of subjects: 48
Study 34278530 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 48
Study 33686407 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 150 IU dose proposed by the OPTIMIST trial
Number of subjects: 2677
Study 33686407 — intervention group
Group type: COMPARATOR
Intervention: Starting dose >300 IU
Number of subjects: 2677
Study 32960920 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive playing strategy
Number of subjects: 12
Study 32960920 — intervention group
Group type: EXPERIMENTAL
Intervention: Active playing strategy
Number of subjects: 12
Study 32960920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed playing strategy
Number of subjects: 12
Study 32960920 — intervention group
Group type: COMPARATOR
Intervention: Control condition (own strategy)
Number of subjects: 12
Study 33712478 — intervention group
Group type: EXPERIMENTAL
Intervention: CLS-TA
Number of subjects: 33
Study 33712478 — intervention group
Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 33
Study 34652514 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical CT‐free navigation (ExactechGPS)
Number of subjects: 45
Study 34652514 — intervention group
Group type: COMPARATOR
Intervention: Acceleration‐based navigation (KneeAlign2)
Number of subjects: 45
Study 34652514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 45
Study 35477876 — intervention group
Group type: EXPERIMENTAL
Intervention: App conditional feedback group (250 patients) using the medication reminder app for medication and BP check alarms.
Number of subjects: 500
Study 35477876 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (250 patients).
Number of subjects: 500
Study 35477876 — intervention group
Group type: EXPERIMENTAL
Intervention: App conditional feedback group (250 patients).
Number of subjects: 500
Study 33337995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid factor (RF) positive subjects
Number of subjects: 15907
Study 33337995 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-citrullinated peptide antibodies (ACPA) positive subjects
Number of subjects: 15907
Study 33337995 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-year risk of developing rheumatoid arthritis (RA)
Number of subjects: 15907
Study 33337995 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk for developing RA associated with RF
Number of subjects: 15907
Study 33337995 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk for developing RA associated with ACPA
Number of subjects: 15907
Study 33200282 — intervention group
Group type: COMPARATOR
Intervention: 37% phosphoric acid (SD-CT)
Number of subjects: 32
Study 33200282 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid with 2% chlorhexidine (CAD-CHX)
Number of subjects: 32
Study 33200282 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% phosphoric acid with 2% grape seed extract (CAD-GSE)
Number of subjects: 32
Study 32015212 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (CMR; 6% dextrose)
Number of subjects: 8
Study 32015212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 35838130 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Needlescopic Enucleation of the Prostate (BNEP)
Number of subjects: 214
Study 35838130 — intervention group
Group type: COMPARATOR
Intervention: Bipolar Vapoenucleation of the Prostate (BVEP)
Number of subjects: 214
Study 35602281 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 140
Study 35602281 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management
Number of subjects: 140
Study 33399175 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland therapy (central or unilateral postero‐anterior pressure) for 2 sessions/week for 3 weeks
Number of subjects: 44
Study 33399175 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan sustained natural apophyseal glides for 2 sessions/week for 3 weeks
Number of subjects: 44
Study 34059737 — intervention group
Group type: EXPERIMENTAL
Intervention: Program B (fixed-order, internet cognitive behavioral therapy, iCBT)
Number of subjects: 951
Study 34059737 — intervention group
Group type: EXPERIMENTAL
Intervention: Program A (free-choice, multimodule stress management)
Number of subjects: 951
Study 34059737 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 951
Study 32029495 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI/5-FU/folinic acid
Number of subjects: 102
Study 32029495 — intervention group
Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 102
Study 35361325 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% urea containing hydrophilic petrolatum
Number of subjects: 30
Study 35361325 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% urea containing hydrophilic petrolatum
Number of subjects: 30
Study 35361325 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial products
Number of subjects: 30
Study 35361325 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial emollient
Number of subjects: 30
Study 35361325 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial formulation
Number of subjects: 30
Study 35361325 — intervention group
Group type: COMPARATOR
Intervention: Cream-based formulation
Number of subjects: 30
Study 35361325 — intervention group
Group type: COMPARATOR
Intervention: No treatment area
Number of subjects: 30
Study 36240972 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Tremelimumab
Number of subjects: 823
Study 36240972 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 823
Study 35753770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Number of subjects: 60
Study 35118971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based interactive distraction
Number of subjects: 70
Study 33614699 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprasorb CNP
Number of subjects: 34
Study 33614699 — intervention group
Group type: COMPARATOR
Intervention: AB‐Thera
Number of subjects: 34
Study 33614699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 34
Study 35686900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% permethrin and oral placebo (Group A)
Number of subjects: 120
Study 35686900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical placebo cream and oral ivermectin (Group B)
Number of subjects: 120
Study 35686900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% gamma benzene hexachloride and oral placebo (Group C)
Number of subjects: 120
Study 35686900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% permethrin and oral ivermectin (Group D)
Number of subjects: 120
Study 33357109 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) and superficial durotomy surgery (Group 2)
Number of subjects: 54
Study 33357109 — intervention group
Group type: COMPARATOR
Intervention: Classic PFD and duraplasty (Group 1)
Number of subjects: 54
Study 32392715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Treatment (ILT) - diet plus exercise with monthly visits
Number of subjects: 76
Study 32392715 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 76
Study 33887952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge peer health navigator intervention
Number of subjects: 144
Study 33470646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonometric blood pressure monitor (Bpro; HealthSTATS International, Singapore)
Number of subjects: 33
Study 33470646 — intervention group
Group type: COMPARATOR
Intervention: Oscillometric cuff-based device (Oscar 2; Sun Tech Medical)
Number of subjects: 33
Study 35689818 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate tablets (OST)
Number of subjects: 110
Study 35689818 — intervention group
Group type: COMPARATOR
Intervention: 2 L polyethylene glycol and ascorbate (PEG/Asc)
Number of subjects: 110
Study 33011852 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 3
Study 33817938 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV patients
Number of subjects: 379
Study 33817938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 379
Study 33817938 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR equations
Number of subjects: 379
Study 32367437 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta plus temozolomide (TMZ)
Number of subjects: 122
Study 32367437 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) alone
Number of subjects: 122
Study 32780234 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible endoscopic myotomy (window technique)
Number of subjects: 106
Study 32780234 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cervicotomy
Number of subjects: 106
Study 32780234 — intervention group
Group type: COMPARATOR
Intervention: Rigid endoscopy
Number of subjects: 106
Study 32780234 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible endoscopy
Number of subjects: 106
Study 32780234 — intervention group
Group type: COMPARATOR
Intervention: Cervicotomy
Number of subjects: 106
Study 33180253 — intervention group
Group type: EXPERIMENTAL
Intervention: Maisha intervention
Number of subjects: 1039
Study 33180253 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1039
Study 32818553 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU/TT based conditioning regimen
Number of subjects: 56
Study 32818553 — intervention group
Group type: COMPARATOR
Intervention: BEAM (non-thiotepa) based conditioning regimen
Number of subjects: 56
Study 35098682 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics score (rad-score) for patients with EGFR mutations
Number of subjects: 1092
Study 35098682 — intervention group
Group type: COMPARATOR
Intervention: Radiomics score (rad-score) for patients with EGFR wild-type
Number of subjects: 1092